Table 1. Clinical and pathological characteristics of all patients.
| Characteristics | No. | % |
|---|---|---|
| Total | 22 | 100.0 |
| Gender | ||
| Male | 21 | 95.5 |
| Female | 1 | 4.5 |
| Age at …, years | ||
| Primary treatment, IQR | 68.2 | 60.2–73.1 |
| UC recurrence, IQR | 70.6 | 61.9–74.9 |
| Time to UC recurrence, months | ||
| IQR | 28 | 11.1–48.6 |
| ASA score | ||
| 0 | 0 | 0 |
| 1 | 2 | 9.1 |
| 2 | 14 | 63.6 |
| 3 | 5 | 22.7 |
| 4 | 1 | 4.5 |
| 5 | 0 | 0 |
| ECOG score | ||
| 0 | 3 | 13.6 |
| 1 | 16 | 72.7 |
| 2 | 3 | 13.6 |
| Metastasis site | ||
| Pulmonary | 13 | 59.1 |
| Loco-regional | 3 | 13.6 |
| Hepatic | 2 | 9.1 |
| Adrenal | 1 | 4.5 |
| Testicular | 1 | 4.5 |
| Nodal above aortic bifurcation | 1 | 4.5 |
| Renal transplant | 1 | 4.5 |
| CHT prior to metastasectomy | 2 | 9.1 |
| Primary treatment | ||
| Cystoprostatectomy | 14 | 63.6 |
| Nephro-ureterectomy | 3 | 13.6 |
| Maximal TURBT | 3 | 13.6 |
| Complete urinary tract extirpation | 1 | 4.5 |
| Pelvic exenteration | 1 | 4.5 |
| Neoadjuvant CHT primary | 3 | 13.6 |
| BC staging | ||
| Total | 20 | 100.0 |
| pT stage | ||
| T1 | 8 | 40.0 |
| ≥T2 | 12 | 60.0 |
| pN stage | ||
| N0 | 15 | 75.0 |
| N+ | 2 | 10.0 |
| Nx | 3 | 15.0 |
| UTUC staging | ||
| Total | 6 | 100.0 |
| pT stage | ||
| T1 | 5 | 83.3 |
| ≥T2 | 1 | 16.7 |
| pN stage | ||
| N0 | 2 | 33.3 |
| N+ | 3 | 50.0 |
| Nx | 1 | 16.7 |
UC, urothelial cancer; IQR, interquartile range; ASA score, American Society of Anesthesiologists score; BC, bladder cancer; ECOG, Eastern Cooperative Oncology Group; CHT, chemotherapy; UTUC, upper urothelial tract cancer; pT stage, pathological tumor stage; pN stage, pathological nodal stage.